Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Sven‐Thorsten Liffers

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5033665415. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 9

  1. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  2. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Co-author DOI 10.1186/s13148-024-01623-z↗
  3. Differential miRNA and Protein Expression Reveals miR-1285, Its Targets TGM2 and CDH-1, as Well as CD166 and S100A13 as Potential New Biomarkers in Patients wi… Co-author DOI 10.3390/cancers16152726↗
  4. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  5. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols. Co-author DOI 10.1159/000529452↗
  6. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  7. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  8. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Co-author DOI 10.1038/s41420-020-0246-7↗
  9. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. Co-author DOI 10.1158/0008-5472.can-18-0052↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Thomas Siveke · 8 shared papers, 2018–2026 · strength 1.01
  2. Marija Trajkovic‐Arsic · 5 shared papers, 2018–2026 · strength 0.63
  3. Laura Godfrey · 3 shared papers, 2023–2026 · strength 0.52
  4. Diana Behrens · 3 shared papers, 2020–2026 · strength 0.47
  5. Phyllis F. Cheung · 4 shared papers, 2018–2026 · strength 0.46
  6. Rita Teresa Lawlor · 2 shared papers, 2024–2026 · strength 0.37
  7. Aldo Scarpa · 2 shared papers, 2024–2026 · strength 0.37
  8. Steven A. Johnsen · 2 shared papers, 2020–2024 · strength 0.26
  9. Juanfei Peng · 1 shared paper, 2026 · strength 0.20
  10. Markus Vogt · 1 shared paper, 2026 · strength 0.20
  11. Elmar Wolf · 1 shared paper, 2026 · strength 0.20
  12. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.20
  13. Niklas Krebs · 1 shared paper, 2026 · strength 0.20
  14. Rickmer Braren · 1 shared paper, 2026 · strength 0.20
  15. Smiths Lueong · 2 shared papers, 2020–2022 · strength 0.20
  16. Xin Zhang · 2 shared papers, 2020–2022 · strength 0.19
  17. Stephan A. Hahn · 2 shared papers, 2020 · strength 0.19
  18. Theodoros Kolokotronis · 1 shared paper, 2024 · strength 0.17
  19. Marie Buchholz · 1 shared paper, 2024 · strength 0.17
  20. Britta Majchrzak‐Stiller · 1 shared paper, 2024 · strength 0.17
  21. Matthias Glanemann · 1 shared paper, 2024 · strength 0.17
  22. Waldemar H. Uhl · 1 shared paper, 2024 · strength 0.17
  23. Chris Braumann · 1 shared paper, 2024 · strength 0.17
  24. Philipp Höhn · 1 shared paper, 2024 · strength 0.17
  25. Barbara Sitek · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.